Tirzepatide and Retatrutide: What Separates a Dual Agonist from a Triple

These are the two most expensive compounds in this catalogue, and the question that decides between them is usually framed as "which one works better." The published trials do not answer that question, because the two have never been compared against each other. What the trials do answer is a more useful question: what each one has actually been shown to do, and how much evidence stands behind each answer.

The mechanical difference: two receptors or three

Tirzepatide is a dual agonist. It activates the GIP and GLP-1 receptors, the two incretin pathways that govern how strongly the body registers fullness after a meal and how it handles the resulting glucose load.

Retatrutide activates those same two receptors and adds a third: the glucagon receptor. This is the part worth understanding, because glucagon is counterintuitive here. GLP-1 and GIP signalling largely act on the intake side of the equation, by reducing how much is eaten. Glucagon receptor activity is associated in the research literature with the output side, energy expenditure. A compound that engages both sides is working on a different arithmetic than one that only reduces intake.

That is the theory. What follows is what the trials measured.

What the tirzepatide trials showed

SURMOUNT-1 is a phase 3 trial, which is the stage at which a compound is tested at scale against placebo with predefined endpoints. It enrolled 2,539 adults with obesity, or with overweight plus at least one weight-related condition, excluding diabetes, and ran for 72 weeks including a 20-week dose escalation.

Mean weight change at 72 weeks was −15.0% on 5 mg weekly, −19.5% on 10 mg and −20.9% on 15 mg, against −3.1% on placebo. A reduction of 5% or more occurred in 85% to 91% of participants depending on dose, against 35% on placebo.

The number that matters most for interpretation is 2,539. A result of this size, at phase 3, with a placebo arm, is a different class of evidence from a promising early trial, regardless of how large the percentages are in either.

What the retatrutide trials showed

The phase 2 obesity trial enrolled 338 adults and ran for 48 weeks, testing 1, 4, 8 and 12 mg once weekly against placebo.

Mean weight change at 48 weeks was −8.7% on 1 mg, −17.1% on 4 mg, −22.8% on 8 mg and −24.2% on 12 mg, against −2.1% on placebo. At 12 mg, 83% of participants had a reduction of 15% or more.

A separate phase 2 trial in people with type 2 diabetes tested the same compound against both placebo and an active comparator.

Reading the two side by side, carefully

The temptation is to line up −24.2% against −20.9% and conclude that retatrutide is the stronger compound. That comparison is not supported, for three reasons worth stating plainly.

The trials enrolled different populations over different durations. One ran 48 weeks, the other 72. Participants differed in baseline characteristics. Trials that are not designed for comparison cannot be compared by lining up their headline numbers.

The evidence is at different stages. Phase 2 results frequently do not survive phase 3 at the same magnitude, which is a routine pattern across drug development rather than a criticism of any particular compound. Retatrutide's phase 3 obesity programme was still in progress at the time of writing.

The sample sizes differ by almost an order of magnitude. 338 against 2,539 changes how much confidence a percentage carries, independent of the percentage itself.

What can be said is narrower and more defensible: both compounds produced substantial, dose-dependent weight reduction against placebo in their own trials, and tirzepatide's result is supported by the more mature evidence base.

Where the two agree

Both trials reported gastrointestinal events as the most common adverse events, and in both the effects were dose-related and mostly mild to moderate. In the retatrutide trial, starting at a lower dose partially mitigated them, which is why the trial tested two different starting doses for the same target dose.

The retatrutide trial also reported dose-dependent increases in heart rate that peaked at 24 weeks and declined afterwards. This is the kind of detail that tends to disappear from summaries, and it is one of the reasons the source links below matter more than this page does.

What this does not tell you

Neither trial establishes anything about use outside its own protocol, and no trial discussed here involved the compounds as supplied for research use. The doses above are what was administered under medical supervision in a clinical trial, recorded here because that is what the published record says, not as a suggestion of what anyone should do.

Research-use-only

This article summarises publicly available clinical trial literature. These compounds are supplied for research purposes only, are not approved for human or veterinary use, and nothing here constitutes medical advice or a dosing recommendation.